Search PubMed⌕ Search

Biomedical subjects

M W Wang

Publications and source records attributed to M W Wang.

At least 37 records · Page 2Linked to original sources

Aberrant maternal behaviour in mice treated with a progesterone receptor antagonist during pregnancy.

The rapid onset of normal maternal behaviour after parturition in mice, consisting of cleaning, warming, feeding and protection of offspring, is primed by oestrogen, progesterone and oxytocin. Previous studies showed that passive transfer of monoclonal antibodies against progesterone significantly increases the incidence of maternal rejection of pups. To test the hypothesis that aberrant maternal behaviour is due to partial progesterone withdrawal leading to hormonal imbalance during late pregnancy, maternal rejection was assessed following treatment with a progesterone receptor antagonist. Mifepristone (RU486) was given subcutaneously on either day 2 (100 micrograms) or day 17 (50 micrograms) of pregnancy, or on the first day of lactation (100 micrograms). Maternal behaviour was monitored twice daily for the first 6 days of lactation and pup rejection recorded for a further 15 days. Maternal rejection was significantly greater after mifepristone administration on either day 2 or day 17 (28.6% and 38.3%) compared with controls (11.1% and 5.2% respectively). Rejection was negligible in both treated and control groups if mifepristone was given after parturition. When mothers were treated at day 17, the length of the latent period before pups were retrieved and returned to the nest was markedly increased in mifepristone-treated mothers (46.3 s) compared with controls (4.4 s) though the effect was transient. The results indicate that mifepristone interferes with the hormonal priming mechanism(s) necessary for the onset of normal maternal behaviour by a receptor-mediated effect. The similarity of the present results and those obtained with anti-progesterone antibodies implies that receptor antagonism or antibody scavenging of progesterone influence a common central nervous mechanism that is essential for the normal priming process.

Animals↗

Anti-progesterone effects on maternal recognition and behaviour imprinted during first pregnancy in mice.

Anti-progesterone treatment using specific anti-progesterone antibodies or a progesterone receptor (PR) antagonist during first pregnancy impairs postpartum maternal behaviour in mice. This effect is demonstrable only if the treatment is given during pregnancy but not immediately after parturition. The purpose of the present studies was to investigate if maternal behaviour is also impaired by anti-progesterone treatment in subsequent pregnancies. Studies with a monoclonal antibody to progesterone (DB3; 4.5 nmol/mouse) showed that injection of females on day 17 of second pregnancy did not cause maternal rejection but the latency of pup retrieval was prolonged especially during the first 3 days of lactation. This phenomenon was not observed in animals that had previous experience of full length lactation. Experiments were carried out with mifepristone (RU486; 10 micrograms/mouse) injected at day 17 of first, second or third pregnancies. Pup rejection (22.5% vs 12.3%) and prolongation of the retrieval latency (62.3 +/- 13.3 vs 19.7 +/- 6.5 s; P < 0.02) were observed following the first pregnancy. No abnormal behavioural effects were found in mothers treated in second or third pregnancy who had prior full length lactation experience. Control females subjected to only one pup retrieval test after first delivery rejected their pups if treated in their second pregnancy (27.3% vs 4.4%; P < 0.001) and displayed a marginal prolongation of the retrieval latency period (20.9 +/- 7.0 vs 7.4 +/- 2.6 s). Anti-progesterone treatment had no negative influence when administered during third pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment.

The brain isozyme of creatine kinase (CKB) is a major component of the estrogen-induced proteins in the rat uterus. Hormonal specificity of this response was studied in cotransfection assays using the rat CKB promoter linked to the bacterial chloramphenicol acetyltransferase gene. Response was specific for estrogen as 17 beta-estradiol in the presence of estrogen receptor dramatically stimulated the CKB promoter. This induction was completely blocked by the estrogen antagonist ICI 164,384. Nuclear receptors for progesterone, androgen, glucocorticoid and vitamin D did not significantly activate the CKB promoter in the presence of their respective ligands. Creatine kinase (CK) activity was analyzed in decidualized mouse uterus to assess estrogenic activity in vivo. Upon oil stimulation, uterine horns of day 4 pseudopregnant mice underwent a dramatic outgrowth in response to endogenous progesterone. This response was accompanied by a significant decrease in CK activity from a control value of 1.44 +/- 0.25 to 0.38 +/- 0.08 IU/mg protein (P < 0.001), indicating that the action of estrogen was suppressed. Treatment of females one day prior to oil-stimulation with progesterone receptor antagonists, RU486 (Mifepristone) or ZK299 (Onapristone), or with a monoclonal antibody to progesterone (DB3), abolished decidualization, and also restored the CK activity to the control value. These results suggest that CK can be used as a specific cellular marker to detect unopposed estrogen action in the mouse uterus associated with progesterone withdrawal or receptor blockade.

Animals↗

Abortifacient effects in the pregnant hamster of an antibody to progesterone are reversed by exogenous prolactin.

A single i.p. injection of 10 nmol of a monoclonal antibody to progesterone (mAb-P4) on Day 4 of pregnancy (day of nidation) interrupts pregnancy by Day 8 (Day 1 = sperm-positive smear) in 75% of treated hamsters (n = 8). This correlates with structural and functional luteolysis, significantly (p < 0.05) reduced serum prolactin (PRL), and a nonsignificant trend for reduced FSH (which constitute the minimal luteotropic complex of the hamster), but LH is unchanged. Embryos implant and develop normally for a while, but by Day 8 the uterus is distended with the resorbing products of conception. The abortifacient effects of passive immunization against progesterone are reversed 100% by s.c. injection of 100 micrograms PRL daily on Days 4-7; deferring PRL treatment until Days 6-7 maintained pregnancy in 75% of the animals, still significantly different from the untreated mAb-P4 group. Injection of 50 micrograms PRL on Days 4-7 maintains pregnancy in 50% of the mAb-P4-treated hamsters (not significantly different), whereas 10 micrograms PRL on Days 4-7 is wholly ineffective. No dose of FSH (0.1-10.0 micrograms) or LH (0.4-2.0 micrograms) on Days 4-7 reversed the effects of mAb-P4; neither did 10 micrograms PRL plus 0.4 or 2 micrograms of FSH. The maintenance of pregnancy after 100 micrograms PRL on Days 4-7 is associated with normal serum levels of PRL, FSH, and LH and no change in the serum concentration of the mAb-P4 antibody.(ABSTRACT TRUNCATED AT 250 WORDS)

Abortifacient Agents↗

The variant mRNA isoform of human metastasis gene (CD44V) detected in the cell lines of human hepatocellular carcinoma.

The interaction of the cell surface receptor CD44 molecular with its ligands (addressin, extracellular matrix etc.,) plays an important role in fulfilling the lymphocyte homing and immune reaction. Recently alternatively spliced products of CD44 gene are found to be involved in tumor metastasis as well. Our report found that CD44 prototype RNA (CD44S) was present in all five tumor cell lines. Isoform CD44 RNA (CD44V) was recognized in three metastasized hepatocellular carcinoma cell lines, J5, HCC36, HEP3B. In addition, the J5 CD44 RNA isoform expressed two distinct transcripts which are of the same size as MDA-231 breast tumor cell line. The MDA-231 CD44 RNA variant (CD44V) has been confirmed to contain metastasis domain 4 and 5. It is implicated that the alternative RNA splicing may also play a major role in hepatocellular carcinoma metastasis.

Base Sequence↗

[Puerperal infection of ureaplasma urealyticum].

Using indirect agglutination test (IAT), ELISA and metabolic inhibition test (MI), serum specific IgM antibodies to ureaplasma urealyticum (Un) was investigated in 160 women of late pregnancy during the period of 1991-1992. 81 cases (50.6%) were found positive. 65 out of 81 positive mothers had umbilical blood samples examined and placenta tissues cultured. Specific IgM was detected in the umbilical blood of 7 women (10.8%), and ureaplasma urealyticum was isolated from 6 placenta (9.2%). Among Un IgM positive women, 28 (34.6%) were complicated with puerperal fever, and 30 newborns suffered from neonatal pneumonia and fever, which were significantly higher than that in the Un IgM negative group (P < 0.05). This study indicated that ureaplasma urealyticum might be one of the important pathogens for puerperal and neonatal infection.

Adult↗

Evidence for release of free glucose from muscle during amylin-induced glycogenolysis in rats.

Amylin, a 37 amino acid product of pancreatic beta-cells, inhibits insulin-stimulated radioglucose incorporation into muscle glycogen. In the current study, we exercised rats and then prelabelled the glycogen pool by infusing [3-3H]glucose along with glucose and insulin. Subsequent amylin administration increased the rate of appearance of tritiated water 6.4-fold, consistent with stimulation of glycogenolysis and passage of the released moieties through the hexose --> triose step of glycolysis. Further, there was an increase in plasma [3-3H]glucose after amylin, consistent with the release of free glucose previously sequestered in muscle glycogen. Calcitonin gene-related peptide (8-37), an amylin antagonist, prevented these actions.

Amyloid↗

Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat.

Amylin, a 37 amino-acid peptide secreted from the pancreatic beta-cells, exerts marked effects on carbohydrate metabolism in intact rats. It has approximately 50% amino-acid identity with the calcitonin gene-related peptides (CGRP) as well as certain shared biological actions. In vivo potencies were determined for four responses (increases in plasma glucose, increases in plasma lactate, decreases in plasma calcium, and depression of arterial pressure). These responses were measured in fasted, lightly anaesthetized rats given single intravenous bolus injections of rat amylin or rat CGRP alpha at doses of 0.01, 0.1, 1, 10, 100 and 1000 micrograms (about 7 pmol/kg-700 nmol/kg). Control animals received an equal volume of saline. The order of potency for the different responses was as follows: (i) increase in plasma glucose concentration, amylin approximately 2 times more potent than CGRP (by ED50) with detectable responses occurring at doses 100-fold less; (ii) decrease in plasma total calcium concentration, CGRP of equal or greater potency than amylin; and (iii) decrease in arterial pressure, CGRP 44-fold more potent than amylin. An increase in plasma lactate occurred with amylin doses 1000-fold lower than the CGRP doses producing such effects. Saturation of the dose-dependent increase in lactate was not observed, so median effective doses (ED50) were not obtained. These results are consistent with the existence of separate receptor systems for amylin and CGRP. The effects of amylin on plasma glucose and lactate concentrations were demonstrable at doses of 0.1-1.0 micrograms (70-700 pmol/kg). These doses produced plasma levels that were within the concentration range previously reported for insulin-resistant rats, supporting the proposal that amylin is a physiologic endocrine regulator of carbohydrate metabolism in vivo.

Amyloid↗

Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats.

The actions of intravenous glucagon and amylin, a newly discovered hyperglycemic pancreatic islet hormone, have been compared in 20-h fasted and fed, lightly anesthetized rats, and in rats made hypoglycemic with an insulin infusion. In fasted animals, amylin (75 nmol/kg) was more effective than glucagon (90 nmol/kg) in increasing plasma glucose (glucose increment 4.55 vs. 1.71 mM, P < 0.001). Amylin elicited a marked increase in plasma lactate, as previously reported, whereas glucagon did not alter plasma lactate. In fed animals, glucagon elicited twice as much increase in plasma glucose as did amylin; amylin again elicited a marked lactate increase that was greater (increment 1.45 vs. 0.97 mM, P < 0.05) and more prolonged than in the fasted state, whereas glucagon was without effect on lactate levels. These findings are consistent with glucagon's known action to promote hyperglycemia from hepatic glycogenolysis and amylin's demonstrated action to promote muscle glycogenolysis and increase lactate supply to the liver. Infusions of sodium lactate that produced plasma lactate increments similar to those evoked by 75 nmol/kg amylin evoked patterns of glucose response in fasted and fed rats similar to those evoked by amylin. Thus increased lactate supply to the liver may account for amylin's hyperglycemic effects. Amylin and glucagon could each restore plasma glucose to control levels in fasted animals made hypoglycemic by insulin infusion (plasma glucose reduced to 3.3 mM). A bolus of 75 nmol/kg amylin was more effective than 180 nmol/kg glucagon, restoring basal glucose levels for > 3 h, whereas glucagon restored it for < 1 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Amyloid↗

Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement.

Mouse cells expressing the human complement regulatory proteins decay accelerating factor (DAF) or membrane cofactor protein (MCP) were produced both by hybridoma technology and by transfection with the appropriate cDNAs. The expression of either or both of these products protected the mouse cell from lysis by human (though not rabbit) complement in the presence of naturally occurring human anti-mouse antibody. This effect could be abrogated by the addition of monoclonal antibody against DAF or MCP. These data suggested that the production of animals transgenic for human complement regulatory proteins should in principle be similarly protected from hyperacute xenograft rejection.

Animals↗

Immunofluorescent localization of pig complement component 3, regardless of the presence or absence of detectable immunoglobulins, in hyperacutely rejected heart xenografts.

Rabbit heart xenografts transplanted into the neck of newborn pigs were all hyperacutely rejected within two hours regardless of the presence or absence of detectable endogenous immunoglobulins (Ig). Cryostat tissue sections were prepared from the rejected rabbit hearts and incubated with sheep polyclonal antibodies against pig complement component 3 (C3), pig IgG and pig IgM. Specific immunoreaction was visualized by fluorescein-conjugated antibodies to sheep IgG. C3 was localized mainly on the surfaces of vascular endothelial as well as myocardial cells, and the localization was not dependent upon the presence of pig immunoglobulins within the same tissue. Both pig IgG and IgM were detected only in the heart xenografts transplanted into suckled pigs, whereas no trace of immunoglobulin was found in those transplanted into circulating antibody-free presuckled pigs. Treatment with cobra venom factor (which inhibits complement activity) prior to transplantation prolonged xenograft survival and completely abolished C3 immunostaining. The results provide new evidence at the histochemical level that the alternative pathway of complement is involved in hyperacute xenograft rejection of the species combination (rabbit to pig) used in this study.

Animals↗

Proto-oncogene erbA expression and increased abundance of progesterone receptors in the mouse uterus after passive immunisation against progesterone before implantation.

Passive immunisation with a monoclonal anti-progesterone antibody (DB3) prevents pregnancy in the mouse, and antibody is localised in the endometrium before the onset of implantation. BALB/c female mice were injected intraperitoneally with 9 nmol of DB3 (a dose known to cause 100% infertility) 32 h post coitum, and the uterus was removed at various times after injection. Using a monoclonal anti-progesterone receptor antibody (PR6), expression of progesterone receptors was found to be abundant in uterine tissue of DB3-treated mice; this was associated with substantial progesterone receptor mRNA levels and with maximum localisation of DB3 antibody as detected by anti-idiotype antibody. Control animals treated with an equal amount of the mouse myeloma protein P3 showed very low levels of progesterone receptor in the uterus. DB3 treatment also affected uterine expression of the proto-oncogene erbA product (which shows primary sequence homology with the progesterone receptor) as revealed by specific antiserum to the ERBA protein and by in situ hybridisation with a cDNA probe to v-erbA. Time-course studies indicated that the erbA gene was expressed at a high level before progesterone receptor expression increased, that its expression was dependent on the presence of the embryo and that erbA expression persisted longer in DB3-treated females. The observations suggest that anti-progesterone immunisation has a direct effect within the uterus, involving persistence of proto-oncogene erbA expression (which itself may represent an early maternal response to pregnancy) and increased progesterone receptor levels resulting from an unopposed oestrogen effect derived from local ligand withdrawal.

Amino Acid Sequence↗

Biotinylated anti-progesterone monoclonal antibodies specifically target the uterine epithelium and block implantation in the mouse.

Post-coital administration of a mouse monoclonal antibody (mAb) against progesterone (DB3; IgG1) prevents pregnancy in several species. Our previous studies in mice have shown that passively transferred DB3 specifically targets the uterus before the expected time of implantation, probably through progesterone-binding sites. DB3 and two other anti-progesterone mAbs, i.e. 11/34 (IgG1) and 11/64 (IgM), were biotinylated and 9 nmol of each (a dose known to reduce pregnancy rate by greater than 80% with unconjugated mAbs) was injected into BALB/c female mice 32 h post coitum (p.c.). The biotin-mAb complexes were highly effective in blocking pregnancy (83-100%) compared with control animals that had received the biotinylated MOPC21 myeloma protein P3 (IgG1). Using the streptavidin-FITC (fluorescein isothiocyanate) reporter complex or second-stage anti-biotin-FITC antibodies, biotinylated conjugates of DB3, 11/34 and 11/64 were specifically localized on the uterine luminal epithelium at 68 h p.c. (i.e. 36 h after i.p. injection). Neither P3-biotin-treated pregnant mice nor biotinylated anti-progesterone mAb-treated pseudopregnant females showed a positive reaction. In addition, the localization of biotin-conjugated anti-progesterone mAbs could be blocked by absorption of the antibodies with free progesterone or progesterone conjugates prior to injection. These results show that localization to the uterine epithelium occurs with different anti-progesterone mAbs, and that this phenomenon is probably associated with progesterone-binding sites on the luminal epithelium.

Animals↗

8-37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats.

When 2 mmol L-arginine was infused into non-fasted, anesthetized rats at a rate slow enough to avoid hemodynamic disturbance, there was a rise in plasma glucose concentration followed by a decline to pre-infusion levels. In animals pre-infused with 8-37hCGRP, a fragment of calcitonin gene-related peptide that blocks amylin's hyperglycemic action, the normal initial rise in plasma glucose was accompanied by an enhanced rise in plasma insulin and was then followed by an enhanced fall in plasma glucose. These perturbations of the insulin and glucose response during amylin receptor blockade are difficult to explain without invoking a role for endogenous amylin; they further suggest an autocrine/paracrine role for amylin at the pancreatic islet.

Amyloid↗

Antibodies, implantation and embryo survival.

The diverse strategies adopted among species for the maintenance of luteal function converge to meet the indispensable requirement for this hormone particularly at the time of onset of implantation. What has emerged from immunization studies is the difference that exists between various species in the effects of progesterone depletion. The findings affirm the uterus as a primary site of progesterone action in the preimplantation period of gestation in the mouse, whereas in the hamster the positive feedback by progesterone on pituitary luteotrophin secretion is important in maintaining luteal function and hormone secretion at a level necessary for uterine preparation. The impact of progesterone in the rat seems to be established within 48 h after fertilization, whereas in the ferret the hormone's action ensures a suitable uterine environment in which the early embryo can flourish. Its effects in early pregnancy in the marmoset are ambiguous from the present studies unless it emerges that target organ responses are tuned to low concentrations of active steroid. However, the discoveries in mice of a conserved family of immunoglobulin genes used exclusively by immunogenic forms of progesterone conjugated to proteins to stimulate antibody production, and of antibody binding to the uterine epithelium, reveal systems potentially inimical for embryo survival. The endometrial expression of the proto-oncogene erb-A at a time when the embryo has not yet arrived in the uterus, and of antibody-binding to the uterine epithelium, are early maternal responses whose significance require closer examination. The present findings support the hypothesis that the primary site of action of progesterone during the preimplantation period differs between species, and that it is not only the mother that recognizes, but the embryo that initiates early changes before the onset of implantation 'in the bed of soil that nourishes it', a symbiosis that may yet prove to be a common feature of the adoption of viviparity as a preferred mode of reproduction.

Animals↗

Discordant xenograft rejection in an antibody-free model.

Newborn pigs prevented from suckling colostrum were shown to have less than 0.05 micrograms/ml total immunoglobulin present in their serum. Rabbit heart xenografts transplanted heterotopically into the neck of such pigs were hyperacutely rejected, with a mean survival time of 92 +/- 14 min (mean +/- SD). Pigs which had been allowed to suckle and whose serum contained 10-15 mg/ml maternal immunoglobulin hyperacutely rejected rabbit heart xenografts in 109 +/- 62 min. Histological studies showed no Ig binding but complement component 3 (C3) binding to rabbit hearts placed in immunoglobulin-negative pigs. Prolongation of rabbit heart xenograft survival was achieved by administering cobra venom factor (1 mg/kg) to the pigs pretransplant. These data show hyperacute xenograft rejection in the absence of antibody and suggest that its cause is activation of complement by the alternative pathway.

Animals↗

Abnormal maternal behaviour in mice previously immunized against progesterone.

Anti-progesterone immunization leads to reversible infertility in mice; this can be achieved by passive immunization with a monoclonal antibody to progesterone (DB3), or by active immunization with either a progesterone-protein (bovine serum albumin; BSA) conjugate or anti-idiotype directed against DB3. Recovery of fertility in treated females varied from 39.5 to 75.5 median days after passive or active (progesterone-BSA) immunization respectively. Litter size after the first pregnancy also differed from 8.6 +/- 0.8 to 5.0 +/- 0.6 (mean +/- S.E.M.) per mother after passive or active immunization respectively. When litter size was standardized to a maximum of four pups per litter, aberrant maternal responses were observed in the first 5 days after delivery in 40-70% of the nursing mothers. These responses took the forms of cannibalism and failure to retrieve or to nurse pups and resulted in a high incidence of pup rejection (up to 40%), compared with no rejection in control mothers. When mothers were allowed to keep entire litters, an even higher incidence of pup rejection occurred (51% compared with 8% in controls). There was an apparent relation between the degree of negative maternal behaviour and the progesterone antibody concentration in the circulation during the infertile period. Whereas aberrant behaviour occurred mainly within the first 5 days of lactation, it was significantly reduced thereafter. Aberrant behaviour of the mother towards pups may be a consequence of the presence of residual progesterone antibodies in the circulation which affects the process of progesterone withdrawal at parturition that is essential for the establishment of normal maternal responses to the neonate.

Animals↗